Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Texas Health Science Center

Division of University of Texas
www.uthscsa.edu

Latest From University of Texas Health Science Center

Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata

Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.

Regenerative Medicine Business Strategies

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Deals Research & Development

Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

Companies Research & Development

Insmed Phase III Date Support Accelerated Approval For ALIS In Rare Lung Disease

Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in a Phase III study of adult patients with a rare, bacteria-driven lung disease.

Clinical Trials Drug Approval Standards
See All
UsernamePublicRestriction

Register